ethyl 2-(4-tert-butoxycarbonyl-1-piperazinyl)propionate | 886448-02-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(4-tert-butoxycarbonyl-1-piperazinyl)propionate
• 英文别名: t-butyl 4-carboethoxyethyl-1-piperazinecarboxylate；Tert-butyl 4-(1-ethoxy-1-oxopropan-2-yl)piperazine-1-carboxylate
• CAS: 886448-02-8
• 化学式: C₁₄H₂₆N₂O₄
• 分子量: 286.371
• InChiKey: GRIFOPXCHHDBDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-tert-butoxycarbonyl-1-piperazinyl)propionate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 ethyl 2-[4-((2S,4R)-4-benzyloxy-2-pyrrolidinylcarbonyl)-1-piperazinyl]propionate
  参考文献：
  名称：

  Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

  摘要：

  A series of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives were synthesized and evaluated for their activity as VLA-4 antagonists. Of 22 compounds synthesized, 19 compounds showed potent activity with low nanomolar IC50 values. In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12ml/min/kg and 11p 9ml/min/kg). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.058
• 作为产物：
  描述：

  2-溴丙酸乙酯 、 N-Boc-哌嗪 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以56%的产率得到ethyl 2-(4-tert-butoxycarbonyl-1-piperazinyl)propionate
  参考文献：
  名称：

  Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

  摘要：

  A series of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives were synthesized and evaluated for their activity as VLA-4 antagonists. Of 22 compounds synthesized, 19 compounds showed potent activity with low nanomolar IC50 values. In addition, the representative compounds 11o and 11p with a hydroxy group in the pyrrolidine ring showed moderate plasma clearance in rats (11o, 30 ml/min/kg and 11p, 21 ml/min/kg) and in dogs (11o, 12ml/min/kg and 11p 9ml/min/kg). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.058

文献信息

• Carboxysubstituted cyclic carboxamide derivatives
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05977139A1

  公开（公告）日：1999-11-02

  The present invention relates to novel carboxy substituted cyclic carboxamide derivatives of formula (1), ##STR1## and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, coughs and bronchitis.

  本发明涉及新型的带有羧基取代的环戊酰胺衍生物，化学式为(1)，##STR1##及其立体异构体和药学上可接受的盐，以及它们作为速激肽受体拮抗剂的用途。这类拮抗剂在治疗包括哮喘、咳嗽和支气管炎在内的速激肽介导的疾病和症状中很有用。
• CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1077942B1

  公开（公告）日：2005-01-12
• NOVEL CARBOXY SUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES
  申请人：HOECHST MARION ROUSSEL, INC.

  公开号：EP0946545A1

  公开（公告）日：1999-10-06
• US5977139A
  申请人：——

  公开号：US5977139A

  公开（公告）日：1999-11-02
• US6316445B1
  申请人：——

  公开号：US6316445B1

  公开（公告）日：2001-11-13